RANI vs RAPP

Rani Therapeutics Holdings, Inc vs Rapport Therapeutics, Inc. — Valuation Comparison 2026

RANI

Biotechnology
Rani Therapeutics Holdings, Inc
Quality
6.0
out of 10
Value Trap
12
SAFE
Price
$0.95
Last close
Models
6/13
Active
VS

RAPP

Biotechnology
Rapport Therapeutics, Inc.
Quality
4.2
out of 10
Value Trap
12
SAFE
Price
$39.49
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType RANI Fair ValueRANI Upside RAPP Fair ValueRAPP Upside
Bayesian DCF Intrinsic $0.20 -79.4% $11.30 -71.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.03 -96.7% $3.93 -90.0%
Dynamic NAV Asset-Based $0.34 -64.3% $7.06 -82.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RANI vs RAPP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RANI vs RAPP — Which Stock Is More Undervalued?

RANI scores higher with a 6.0/10 quality rating vs RAPP's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rani Therapeutics Holdings, Inc (RANI) and Rapport Therapeutics, Inc. (RAPP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RANI currently trades at $0.95 with a QOC of 6.0/10, while RAPP trades at $39.49 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).